Open-Label Treatment Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

August 17, 2016

Primary Completion Date

August 23, 2017

Study Completion Date

August 23, 2017

Conditions
Opioid Use DisorderOpioid-related Disorders
Interventions
DRUG

RBP-6000

Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.

Trial Locations (29)

16601

Keystone Clinical Solutions, Altoona

29407

Carolina Clinical Trials, Charleston

32256

Amit Vijapura, Jacksonville

32607

Sarkis Clinical Trials, Gainesville

33161

Scientific Clinical Research, North Miami

33319

Innovative Clinical Research, Lauderhill

33805

Meridien Research, Lakeland

35570

Boyett Health Services, Hamilton

39232

Precise Research Centers, Inc., Flowood

44125

Rakesh Ranjan MD & Associates, Inc., Garfield Heights

44708

Neuro-behavioral Clinical Research, Canton

45417

Midwest Clinical Research Center, Dayton

63141

St Louis Clinical Trials, St Louis

66206

Phoenix Medical Research, Prairie Village

70114

Louisiana Research Associates, New Orleans

71101

Louisiana Clinical Research, Shreveport

72211

Woodland International Research Group, Little Rock

73112

Pahl Pharmaceutical Professionals, Oklahoma City

SP Research, PLLC, Oklahoma City

75115

InSite Clinical Research, DeSoto

75243

Pillar Clinical Research, Dallas

89102

Altea Research, Las Vegas

90806

Collaborative Neuroscience Network, Long Beach

94612

Pacific Research Partners, Oakland

97232

CODA, Portland

02720

Stanley Street Treatment and Resources, Fall River

02472

Adams Clinical Trials, Watertown

08009

Hassman Research Institute, Berlin

08002

Center for Emotional Fitness, Cherry Hill

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02896296 - Open-Label Treatment Extension Study | Biotech Hunter | Biotech Hunter